Last €97.35 EUR
Change Today -0.45 / -0.46%
Volume 0.0
XP2 On Other Exchanges
As of 2:08 AM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (XP2) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/14 - €102.95
52 Week Low
09/26/13 - €48.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

salix pharmaceuticals ltd (XP2) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (XP2) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (XP2) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $488.9K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (XP2) Key Developments

Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema

Salix Pharmaceuticals Ltd. and Pharming Group NV announced that the Food and Drug Administration has approved RUCONEST(R) (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks. RUCONEST(R) is a recombinant C1 esterase inhibitor that can be administered by the patient after receiving training by a healthcare provider. HAE attacks stem from a deficiency of the C1 inhibitor protein in the blood. HAE is a rare inherited genetic condition that is often not properly diagnosed until later in a patient's life as the symptoms of an attack can mirror someone experiencing an allergic reaction. Severe, painful swelling can occur at any time, which means most people suffering from HAE deal with the constant fear of when their next attack might surface and how that might impair their lives and those around them.

Salix Pharmaceuticals Receives FDA Approval to Expand the Market for Relistor

Salix Pharmaceuticals received approval from the U.S. Food and Drug Administration to expand the market for Relistor. Specifically, the FDA allowed Salix to market Relistor for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain. Salix will now work with FDA's Division of Gastroenterology and Inborn Errors Products (DGIEP) on product labeling and a proposal for studies to track any major adverse events, specifically related to cardiovascular side effects in patients. Getting to this point wasn't a direct shot for Salix. The company first submitted a supplemental New Drug Application (sNDA) for this expanded marketing of Relistor on August 30, 2011. Nearly a full year later, FDA requested more information from Salix and Progenics Pharmaceuticals, a partner on the drug. Specifically, FDA expressed a concern that there might be a risk associated with the chronic use of this kind of drug in patients that are taking opioids for chronic pain, and called for a large trial to better understand these risks. Salix and Progenics argued that there was enough safety data available to approve the expanded use for Relistor and that it would track any potential side effects in a post-marketing trial, sometimes called a Phase 4 trial because the drug maker runs the trial after a drug's approval as opposed to before. Now, with approval in hand, Salix may expand the marketing of Relistor, but will continue to monitor any potential adverse events. The approved label is very important to a drug company. Although doctors can prescribe drugs for 'off label use,' drug reps are strictly prohibited from marketing the products for anything other than exactly what is on the label. This expanded approval ostensibly expands the market for which Salix can promote Relistor.

Cosmo Technologies Ltd, Salix Pharmaceuticals Ltd. - M&A Call

To discuss on company's definitive merger agreement with Cosmo Technologies Limited


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XP2:GR €97.35 EUR -0.45

XP2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $44.11 USD -0.83
Cubist Pharmaceuticals Inc $61.40 USD -1.11
Jazz Pharmaceuticals Plc $136.81 USD -5.70
Lupin Ltd 1,119 INR -11.25
Santen Pharmaceutical Co Ltd ¥6,100 JPY +60.00
View Industry Companies

Industry Analysis


Industry Average

Valuation XP2 Industry Range
Price/Earnings 100.0x
Price/Sales 7.5x
Price/Book 11.8x
Price/Cash Flow 50.8x
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at